Lexaria Bioscience (LEXX)
(Delayed Data from NSDQ)
$3.43 USD
-0.09 (-2.56%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $3.42 -0.01 (-0.29%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Lexaria Bioscience Corp falls in the month of August.
All items in Millions except Per Share data.
8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1 | 6 | 12 | 1 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 0 | 0 |
Total Current Assets | NA | 2 | 7 | 12 | 2 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 3 | 8 | 13 | 3 |
Liabilities & Shareholders Equity | 8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 0 | 0 | 0 | 0 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 0 | 0 | 0 | 0 |
Shareholders Equity | 8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 49 | 47 | 45 | 30 |
Retained Earnings | NA | -46 | -39 | -32 | -28 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 3 | 8 | 13 | 2 |
Total Liabilities & Shareholder's Equity | NA | 3 | 8 | 13 | 3 |
Total Common Equity | 0 | 3 | 8 | 13 | 2 |
Shares Outstanding | 15.80 | 8.00 | 5.90 | 5.10 | 2.90 |
Book Value Per Share | 0.00 | 0.34 | 1.29 | 2.56 | 0.86 |
Fiscal Year End for Lexaria Bioscience Corp falls in the month of August.
All items in Millions except Per Share data.
8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 9 | 5 | 2 | 1 |
Receivables | NA | 0 | 0 | 1 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 0 | 1 |
Total Current Assets | NA | 9 | 5 | 3 | 2 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 1 | 1 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 10 | 6 | 4 | 3 |
Liabilities & Shareholders Equity | 8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 0 | 0 | 0 | 0 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 0 | 0 | 0 | 0 |
Shareholders Equity | 8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 60 | 54 | 51 | 49 |
Retained Earnings | NA | -49 | -48 | -47 | -46 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 10 | 6 | 3 | 3 |
Total Liabilities & Shareholder's Equity | NA | 10 | 6 | 4 | 3 |
Total Common Equity | 0 | 10 | 6 | 3 | 3 |
Shares Outstanding | 15.80 | 12.80 | 12.30 | 10.20 | 8.00 |
Book Value Per Share | 0.00 | 0.76 | 0.50 | 0.33 | 0.34 |